immunotherapy, adoptive

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
Florian Märkl, Mohamed-Reda Benmebarek, Julius Keyl, Bruno L Cadilha, Martina Geiger, Clara Karches, Hannah Obeck, Melanie Schwerdtfeger, Stefanos Michaelides, Daria Briukhovetska, Sophia Stock, Jakob Jobst, Philipp Jie Müller, Lina Majed, Matthias Seifert, Anna-Kristina Klüver, Theo Lorenzini, Ruth Grünmeier, Moritz Thomas, Adrian Gottschlich, Richard Klaus, Carsten Marr, Michael von Bergwelt-Baildon, Simon Rothenfusser, Mitchell P Levesque, Markus Vincent Heppt, Stefan Endres, Christian Klein, Sebastian Kobold

Journal for ImmunoTherapy of Cancer May 2023, 11 (5) e006436; DOI: 10.1136/jitc-2022-006436
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
Siri Amanda Tvingsholm, Marcus Svensson Frej, Vibeke Mindahl Rafa, Ulla Kring Hansen, Maria Ormhøj, Alexander Tyron, Agnete W P Jensen, Mohammad Kadivar, Amalie Kai Bentzen, Kamilla K Munk, Gitte N Aasbjerg, Jeppe S H Ternander, Christina Heeke, Tripti Tamhane, Christian Schmess, Samuel A. Funt, Julie Westerlin Kjeldsen, Anders Handrup Kverneland, Özcan Met, Arianna Draghi, Søren Nyboe Jakobsen, Marco Donia, Inge Marie Svane, Sine Reker Hadrup

Journal for ImmunoTherapy of Cancer Aug 2023, 11 (8) e006847; DOI: 10.1136/jitc-2023-006847
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
Elizabeth M Holland, John C Molina, Kniya Dede, Daniel Moyer, Ting Zhou, Constance M Yuan, Hao-Wei Wang, Maryalice Stetler-Stevenson, Crystal Mackall, Terry J Fry, Sandhya Panch, Steven Highfill, David Stroncek, Lauren Little, Daniel W Lee, Haneen Shalabi, Bonnie Yates, Nirali Shah

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004483; DOI: 10.1136/jitc-2021-004483
Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
Sonia Guedan, Maik Luu, Delphine Ammar, Paula Barbao, Chiara Bonini, Philippe Bousso, Christian J Buchholz, Monica Casucci, Biagio De Angelis, Emmanuel Donnadieu, David Espie, Beatrice Greco, Richard Groen, Johannes B Huppa, Chahrazade Kantari-Mimoun, Bruno Laugel, Mary Mantock, Janet L Markman, Emma Morris, Concetta Quintarelli, Michael Rade, Kristin Reiche, Alba Rodriguez-Garcia, Juan Roberto Rodriguez-Madoz, Eliana Ruggiero, Maria Themeli, Michael Hudecek, Ibtissam Marchiq

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e003487; DOI: 10.1136/jitc-2021-003487
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells
Sainiteesh Maddineni, John L Silberstein, John B Sunwoo

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004693; DOI: 10.1136/jitc-2022-004693
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
Yi-Chiu Kuo, Cheng-Fu Kuo, Kurt Jenkins, Alfur Fu-Hsin Hung, Wen-Chung Chang, Miso Park, Brenda Aguilar, Renate Starr, Jonathan Hibbard, Christine Brown, John C Williams

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e003752; DOI: 10.1136/jitc-2021-003752
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma
Rosa A van Amerongen, Renate S Hagedoorn, Dennis F G Remst, Danique C Assendelft, Dirk M van der Steen, Anne K Wouters, Marian van de Meent, Michel G D Kester, Arnoud H de Ru, Marieke Griffioen, Peter A van Veelen, J H Frederik Falkenburg, Mirjam H M Heemskerk

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004409; DOI: 10.1136/jitc-2021-004409
PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
Yukiko Yamaguchi, Jackson Gibson, Kevin Ou, Lupita S Lopez, Rachel H Ng, Neena Leggett, Vanessa D Jonsson, Jelani C Zarif, Peter P Lee, Xiuli Wang, Catalina Martinez, Tanya B Dorff, Stephen J Forman, Saul J Priceman

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004400; DOI: 10.1136/jitc-2021-004400
Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
Stefanie Renken, Takahiro Nakajima, Isabelle Magalhaes, Jonas Mattsson, Andreas Lundqvist, Elias S J Arnér, Rolf Kiessling, Stina Linnea Wickström

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004458; DOI: 10.1136/jitc-2021-004458
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
Mikiya Ishihara, Shigehisa Kitano, Shinichi Kageyama, Yoshihiro Miyahara, Noboru Yamamoto, Hidefumi Kato, Hideyuki Mishima, Hiroyoshi Hattori, Takeru Funakoshi, Takashi Kojima, Tetsuro Sasada, Eiichi Sato, Sachiko Okamoto, Daisuke Tomura, Ikuei Nukaya, Hideto Chono, Junichi Mineno, Muhammad Faris Kairi, Phuong Diem Hoang Nguyen, Yannick Simoni, Alessandra Nardin, Evan Newell, Michael Fehlings, Hiroaki Ikeda, Takashi Watanabe, Hiroshi Shiku

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e003811; DOI: 10.1136/jitc-2021-003811

Main menu

immunotherapy, adoptive

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

immunotherapy, adoptive

Pages